Skip to main content
Shanghai Bao Pharmaceuticals Co., Ltd. logo

Shanghai Bao Pharmaceuticals Co., Ltd. — Investor Relations & Filings

Ticker · 2659 HKEX Manufacturing
Filings indexed 33 across all filing types
Latest filing 2026-05-04 Regulatory Filings
Country HK Hong Kong
Listing HKEX 2659

About Shanghai Bao Pharmaceuticals Co., Ltd.

https://www.baopharma.com

Shanghai Bao Pharmaceuticals Co., Ltd., established in 2019, is an innovative biotechnology company focused on the clinical development, industrialization, and commercialization of recombinant protein and antibody-based therapeutics. The company leverages synthetic biology technology and its proprietary subcutaneous (SC) drug delivery platform, Hysorptase, to advance novel biologic candidates. Shanghai Bao maintains a diverse clinical pipeline and has an approved product. Its portfolio includes finished dosage forms such as injectable solutions, lyophilized powder injections, and pre-filled syringes. A key product, Ricefidase (KJ103) Recombinant IgG Cleaving Enzyme, is developed to meet the clinical needs of patients suffering from acute and severe autoimmune diseases, organ transplant recipients, and individuals requiring gene therapy.

Recent filings

Filing Released Lang Actions
FORM OF PROXY FOR THE ANNUAL GENERAL MEETING TO BE HELD ON MAY 26, 2026
Regulatory Filings
2026-05-04 English
NOTICE OF ANNUAL GENERAL MEETING
Regulatory Filings
2026-05-04 English
CIRCULAR OF ANNUAL GENERAL MEETING
Regulatory Filings
2026-05-04 English
VOLUNTARY ANNOUNCEMENT - UNUSUAL PRICE AND TRADING VOLUME MOVEMENTS AND PROPOSED SHAREHOLDING INCREASE BY CONTROLLING SHAREHOLDER AND INTENTION TO PROPOSE SHARE REPURCHASE MANDATE
Regulatory Filings
2026-05-03 English
2025 ANNUAL REPORT
Regulatory Filings
2026-04-27 English
VOLUNTARY ANNOUNCEMENT - HUMAN HYALURONIDASE FOR INJECTION APPROVED FOR MARKETING BY THE NMPA
Regulatory Filings Classification · 1% confidence The document is a voluntary announcement filed on the Hong Kong Stock Exchange disclaiming liability and providing shareholders and investors with the latest corporate development regarding product approval by the NMPA. It is not a financial report, earnings release, management or board change, dividend notice, or any other specific category. Therefore it falls under the general “Regulatory Filings” category (RNS).
2026-04-08 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.